Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.005 AUD | 0.00% |
|
0.00% | -54.55% |
May. 14 | Bioxyne to Release Shares from Escrow; Shares Up 17% | MT |
May. 14 | Bioxyne Subsidiary, CY Biopharma Enter Partnership to Advance Novel Psilocybin Therapies in Australia | MT |
Sales 2022 | 2.48M 1.67M | Sales 2023 | 5.3M 3.57M | Capitalization | 38.03M 25.59M |
---|---|---|---|---|---|
Net income 2022 | - 0 | Net income 2023 | -1M -673K | EV / Sales 2022 | 2.22 x |
Net cash position 2022 | 2.17M 1.46M | Net cash position 2023 | 3.29M 2.21M | EV / Sales 2023 | 6.55 x |
P/E ratio 2022 |
-30.1
x | P/E ratio 2023 |
-13.9
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 22.01% |
3 months | -44.44% | ||
6 months | -54.55% | ||
Current year | -54.55% |
![Extreme 0.005](/images/extremecours_fleche.png)
![Extreme 0.005](/images/extremecours_fleche.png)
![Extreme 0.005](/images/extremecours_fleche.png)
![Extreme 0.005](/images/extremecours_fleche.png)
![Extreme 0.005](/images/extremecours_fleche.png)
![Extreme 0.005](/images/extremecours_fleche.png)
![Extreme 0.005](/images/extremecours_fleche.png)
Managers | Title | Age | Since |
---|---|---|---|
Sam Watson
CEO | Chief Executive Officer | - | 23-05-18 |
Rachel Qian
AUD | Comptroller/Controller/Auditor | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Peng Ho
CHM | Chairman | 65 | 12-10-29 |
Jason Hine
BRD | Director/Board Member | - | 23-05-18 |
Sam Watson
CEO | Chief Executive Officer | - | 23-05-18 |
Date | Price | Change | Volume |
---|---|---|---|
24-07-03 | 0.005 | 0.00% | 2,488 |
24-07-02 | 0.005 | 0.00% | 77,079 |
24-07-01 | 0.005 | 0.00% | 500,000 |
24-06-28 | 0.005 | 0.00% | 196,579 |
24-06-27 | 0.005 | 0.00% | 60,000 |
Delayed Quote Australian S.E., July 02, 2024 at 10:13 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-54.55% | 6.87M | |
+16.59% | 44.44B | |
+41.02% | 39.84B | |
-10.62% | 37.68B | |
+29.92% | 31.46B | |
-9.23% | 27.02B | |
+12.34% | 26.29B | |
+41.53% | 13.8B | |
+31.49% | 12.46B | |
-7.40% | 11.26B |
- Stock Market
- Equities
- BXN Stock